Ferring Pharmaceuticals’ Senior Vice President of Global Manufacturing Supply Chain, Jens Regelin, LED a Delegation to Visit and Conduct Cooperation Exchanges with Hybio Pharmaceuticals
On November 2nd, Jens Regelin, Senior Vice President of Global Manufacturing Supply Chain at Ferring Pharmaceuticals, led a delegation to visit and exchange with Hybio Pharmaceuticals. Both parties engaged in discussions regarding product quality, production capacity, manufacturing processes, and potential future collaborations.
The participants in this exchange included Jens Regelin, the Senior Vice President of Global Manufacturing Supply Chain at Ferring Pharmaceuticals, as well as Nulan Chen, the General Manager of the Zhongshan Factory, and Yongyu Cai, Supply Chain and Finance Director of the Zhongshan Factory. From Hybio Pharmaceuticals, Chairman Shaogui Zeng and CEO Pinxiang Yu warmly welcomed the delegation from Ferring Pharmaceuticals.
They introduced the company’s current main products and market layout and accompanied the visitors on a tour of the research and development center.
During the exchange, Chairman Shaogui Zeng emphasized that since its establishment, Hybio Pharmaceuticals has always prioritized product quality control and continuously improved its production processes. The company has been implementing an internationalization strategy with a focus on” Based in China, with a global outlook” They have benchmarked in international standards in areas such as production line design, production capacity, and quality control. The Wuhan production base is one of the representatives of this effort. Recently, The Pingshan subsidiary’s formulation production base passed an FDA on-site inspection, indicating that the company’s pharmaceutical production, cGMP quality management system, and production facilities have reached international advanced levels, providing strong production capacity support and quality assurance for future collaborations.
Ferring Pharmaceuticals, founded in Sweden in 1950, is a trusted pharmaceutical company in the fields of reproductive medicine, maternal and child health, as well as the treatment of digestive and urological diseases. They have established branch offices in nearly 50 countries and regions globally, benefiting patients and families in 110 countries and regions.
The leadership of Ferring Pharmaceuticals expressed high praise for Hybio Pharmaceuticals’ production processes and research capabilities. Jens Regelin stated that Ferring Pharmaceuticals in committed to helping people worldwide build families and create better lives. They strive to provide the most advanced and safe therapies for the global reproductive medicine and maternal and child health market, with product quality being their top priority. Hybio Pharmaceuticals possesses the capabilities and production capacity to meet Ferring Pharmaceuticals’ market procurement needs, and both parties look forward to the possibility of more cooperation in the future, aiming for resource sharing and mutual success.
Regarding Hybio Pharmaceuticals:
Hybio Pharmaceuticals was founded in 2003 and has always adhered to the development philosophy of “Based in China, with a global outlook.” With peptides as its core, the company seizes international market opportunities and has received “China, the United States, and Europe three reports” for multiple active pharmaceutical ingredients and formulations in China, the United States, and Europe. Currently, they have 26 peptide drugs, 9 new drug certificates, and 24 clinical approvals.
Hybio Pharmaceuticals has a rich reserve of peptide products, particular in peptide active pharmaceutical ingredients and high-barrier peptide injections, forming its own competitive advantages. Their product pipeline focuses on four major therapeutic areas: reproductive medicine support, weight reduction and glucose control, digestive hemorrhage prevention, and anti-infection. As one of the few companies with large-scale peptide active pharmaceutical ingredients globally, Hybio Pharmaceuticals fully leverages its strengths and gradually explores collaborations with high-quality pharmaceutical companies at home and abroad. They consistently implement the internationalization strategy of “Based in China, with a global outlook,” and continue to strive for the protection of human life and health.